Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼º¹®»óºÎ »óÇǼ¼Æ÷¾Ï¿¡¼­ÀÇ ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·áÀÇ ¿ªÇÒ The Role of Primary Radiotherapy for Squamous Cell Carcinoma of the Supraglottic Larynx

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2000³â 18±Ç 4È£ p.233 ~ 243
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿øÅÃ/Won Taek Kim ±èµ¿¿ø/±Çº´Çö/³²ÁöÈ£/Çã¿øÁÖ/Dong Won Kim/Byung Hyun Kwon/Ji Ho Nam/Won Joo Hur

Abstract

¸ñ Àû : º» ¿¬±¸¿¡¼­´Â ºÎ»ê´ëÇб³º´¿ø Ä¡·á¹æ»ç¼±°ú¿¡¼­ ¼º¹®»óºÎ ÆíÆò»óÇǼ¼Æ÷¾ÏÀ¸·Î Áø´Ü¹Þ°í ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº ȯÀÚµéÀ» ´ë»óÀ¸·Î ¹æ»ç¼±Ä¡·á ¼ºÀû°ú ¿©±â¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ¿©·¯ ÀÎÀÚµéÀ» ºñ±³ ºÐ¼®ÇÏ¿© ¼º¹®»óºÎ¾Ï¿¡¼­ÀÇ ¹æ»ç¼±Ä¡·áÀÇ È¿À²¼º°ú
¿ªÇÒ,
±×¸®°í ¾ÕÀ¸·ÎÀÇ Ä¡·á¹æħÀÇ °áÁ¤¿¡ À־ °í·ÁÇØ¾ß ÇÒ ºÎºÐµéÀ» ¾Ë¾Æº¸·Á ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1985³â 8¿ùºÎÅÍ 1996³â 12¿ù±îÁö ¼º¹®»óºÎ¾ÏÀ¸·Î Áø´ÜµÇ¾î ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº ȯÀÚ 32¿¹¸¦ ÈÄÇâÀû ºÐ¼®À» ÅëÇØ ÃÖ¼Ò 29°³¿ù°£ ÃßÀû°üÂû ÇÏ¿´´Ù. 6MV ±¤ÀÚ¼±À» ÀÌ¿ëÇÏ¿© Á¶»ç¿µ¿ª Ãà¼ÒÄ¡·á¹ý°ú Åë»óÀû ºÐÇÒÁ¶»ç ¹æ¹ýÀ¸·Î ¿ø¹ßºÎÀ§¿Í ÁÖÀ§
°æºÎ¸²ÇÁÀýÀ» Æò±Õ 70.2 Gy·Î Ä¡·áÇÏ¿´°í, ÀÌ Áß 13¿¹´Â cisplatin°ú 5-FU·Î À¯µµ Ç×¾ÏÈ­Çпä¹ýÀ» ½ÃÇà¹Þ¾Ò´Ù. º´±âº°·Î´Â 1±â°¡ 5¸í(15.6%), 2±â°¡ 10¸í(31.3%), 3±â°¡ 8¸í(25%), 4±â°¡ 9¸í(28.1%)À̾ú´Ù.
°á °ú : ¿¬±¸ °á°ú 5³â Àüü »ýÁ¸À²°ú ±¹¼ÒÁ¦¾îÀ², ¼º¹®º¸Á¸À²Àº °¢°¢ 51.7%, 65.2%, 65.6%¿´°í, º´±âº°·ÎÀÇ »ýÁ¸À²Àº, 1±â, 2±â, 3±â, 4±â °¢°¢ 80%, 66.7%, 42.9%, 25.0%¿´°í, ±¹¼ÒÁ¦¾îÀ²Àº °¢°¢ 100%, 60.0%, 62.5%, 44.4%¿´À¸¸ç, ¼º¹®º¸Á¸À²Àº °¢°¢ 100%, 70%,
62.5%,
44.4%¿´´Ù. À¯µµ È­Çпä¹ýÀ» ½Ç½ÃÇÑ ±º°ú ¹æ»ç¼± ´Üµ¶ ±º¿¡¼­ »ýÁ¸À², ±¹¼ÒÁ¦¾îÀ² µî¿¡¼­ À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö ¸øÇß´Ù. Ä¡·á½ÇÆи¦ º¸ÀΠȯÀÚ Áß 7¿¹¿¡¼­ ±¸Á¦Àû ¼ö¼úÀ» ½ÃÇàÇß°í ÀÌ Áß 3¿¹¿¡¼­ ¼º°øÇÏ¿´´Ù. Ä¡·á Áß È­Çпä¹ýÀ» º´¿ëÇÑ 1¿¹¿¡¼­ Áß¼º±¸°¨¼ÒÁõÀ¸·Î
ÀÔ¿øÇÏ¿´À¸¸ç, ±× ¿Ü¿¡´Â grade 3 ÀÌ»óÀÇ ±Þ¼º µ¶¼ºÀº °üÂûµÇÁö ¾Ê¾Ò°í, Ä¡·á ÈÄ 2¿¹¿¡¼­ ½ÉÇÑ ÈĵκÎÁ¾À¸·Î ±â°üÀý°³¼úÀ» ¹Þ¾Ò´Ù. ¿ø°ÝÀüÀÌ´Â 4¿¹¿¡¼­ º¸¿´°í(Æó 3¿¹, ³ú 1¿¹), 2¿¹¿¡¼­ ÀÌÂ÷¼º ¿ø¹ß¾ÏÀÌ ¹ß°ßµÇ¾ú´Ù. Tº´±â¿Í Nº´±â, Ãѹæ»ç¼±·®, ±×¸®°í Á¾¾çÀÇ
À°¾ÈÀû
¼Ò°ß µîÀÌ À¯ÀÇÇÑ ¿¹ÈÄÀÎÀÚ¿´´Ù.
°á ·Ð : ´Ù¸¥ ¿¬±¸µéÀÇ °á°ú¿Í ºñ±³ÇØ º¸¾ÒÀ» ¶§, Á¶±â ¼º¹®»óºÎ¾ÏÀÎ °æ¿ì ¹æ»ç¼±Ä¡·á¿Í º¸Á¸Àû ¼ö¼úÀÌ »ýÁ¸À²°ú ±¹¼ÒÁ¦¾îÀ²¿¡ ºñ½ÁÇÑ °á°ú¸¦ º¸À̹ǷΠÈĵαâ´É º¸Á¸ÀÇ È¿°ú°¡ ÁÁÀº ¹æ»ç¼±Ä¡·á ´Üµ¶À¸·Îµµ ±× ¿ªÇÒÀ» ÃæºÐÈ÷ ÇÒ ¼ö ÀÖ´Ù ÇÏ°ÚÀ¸¸ç, ÁøÇàµÈ º´±âÀÇ
°æ¿ì¿¡¼­´Â ¹æ»ç¼± ´Üµ¶ Ä¡·á°¡ ¼ö¼ú°úÀÇ º´ÇÕÄ¡·áº¸´Ù ¿¹ÈÄ°¡ ¿ùµîÈ÷ ÁÁÁö ¾Ê°Ô ³ªÅ¸³ª¹Ç·Î °¡±ÞÀû ¼ö¼ú°ú ¹æ»ç¼±Ä¡·á º´ÇÕ¿ä¹ýÀ» ½ÃµµÇÏ´Â °ÍÀÌ ÁÁ°ÚÀ¸³ª, ¹æ»ç¼±Ä¡·á¸¦ Çؾ߸¸ ÇÏ´Â °æ¿ì¿¡¼­´Â ¼º¹®º¸Á¸À²°ú ±¹¼ÒÁ¦¾îÀ²À» Çâ»ó ½Ãų ¼ö ÀÖ´Â È­Çпä¹ý°úÀÇ
º´¿ëÄ¡·á,
ƯÈ÷ µ¿½Ã È­Çйæ»ç¼±Ä¡·á¿Í ´ÙºÐÇÒ ¹æ»ç¼±Ä¡·á, ±×¸®°í ¹æ»ç¼± ¹Î°¨Á¦ µîÀ» ÀÌ¿ëÇÑ º¸´Ù ´õ Æø ³ÐÀº ¿¬±¸¿Í Ä¡·á°èȹÀÇ ¼ö¸³ÀÌ ÇÊ¿äÇÏ´Ù°í ÇÏ°Ú´Ù.

Background : First of all, this study was performed to assess the result of curative radiotherapy and to evaluate different possible prognostic factors for squamous cell carcinoma of the supraglottic larynx treated at the Pusan National
University
Hospital. The second goal of this study was by comparing our data with those of other study groups, to determine the better treatment policy of supraglottic cancer in future.
Methods and Materials : Thirty-two patients with squamous cell carcinoma of the supraglottic larynx were treated with radiotherapy at Pusan National University Hospital, from August 1985 to December 1996. Minimum follow-up period was 29 months.
Twenty-seven patients (84.4%) were followed up over 5 years. Radiotherapy was delivered with 6 MV photons to the primary laryngeal tumor and regional lymphatics with shrinking field technique. All patients received radiotherapy under conventional
fractionated schedule (once a day). Median total tumor dose was 70.2 Gy (range, 55.8 to 75.6 Gy) on primary or gross tumor lesion. Thirteen patients had induction chemotherapy with cisplatin and 5-fluorouracil (1-3 cycles). Patient distribution,
according to the different stages, were as follows: stage I, 5/32 (15.6%); stage II, 10/32 (31.3%); stage III, 8/32 (25%); stage IV, 9/32 (28.1%).
Results : The 5-year overall survival rate of the whole series (32 patients) was 51.7%. The overall survival rate at 5-years was 80% in stage I, 66.7% in stage II, 42.9% in stage III, 25% in stage IV ( p= 0.0958). The 5-year local control rates
after
radiotherapy were as follows: stage I, 100%; stage II, 60%; stage III, 62.5%; stage IV, 44.4% ( p=0.233). Overall vocal preservation rates was 65.6%, 100% in stage I, 70% in stage II, 62.5% in stage III, 44.4% in stage IV ( p=0.210). There was no
statistical significance in survival and local control rate between neoadjuvant chemotherapy followed by radiotherapy group and radiotherapy alone group. Severe laryngeal edema was found in 2 cases after radiotherapy, emergent tracheostomy was
done.
Four patients were died from distant metastsis, : three in lung, one in brain. Double primary tumor was found in 2 cases, one in lung (metachronous), another in thyroid (synchronous). Ulcerative lesions were revealed as unfavorable prognostic
factor (
p=0.0215), and radiation dose (more or less than 70.2 Gy) was an important factor on survival ( p=0.0302).
Conclusions : The role of radiotherapy in the treatment of supraglottic carcinoma is to improve the survival and to preserve the laryngeal function. Based on our data and other studies, early and moderately advanced supraglottic carcinomas could
be
successfully treated with either conservative surgery or radiotherapy alone. Both modalities showed similar results in survival and vocal preservation. For the advanced cases, radiotherapy alone is inadequate for curative aim and surgery combined
with
radiotherapy should be done in operable patients. When patients refuse operation or want to preserve vocal function, or for the patients with inoperable medical conditions, combined chemoradiotherapy (concurrent) or altered fractionated
radiotherapy
with or without radiosensitizer should be taken into consideration in future.

Å°¿öµå

¼º¹®»óºÎ¾Ï; ¹æ»ç¼±Ä¡·á; ¼º¹®º¸Á¸; Supraglottic cancer; Radiotherapy; Vocal preservation;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS